We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+29.4%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.45B
AUM Growth
+$253M
Cap. Flow
-$255M
Cap. Flow %
-7.4%
Top 10 Hldgs %
43.88%
Holding
127
New
16
Increased
25
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$62.7M
2
BLU
BELLUS Health Inc.
BLU
+$50.1M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$48.2M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$42.4M
5
EW icon
Edwards Lifesciences
EW
+$31.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$38.2M
2
LLY icon
Eli Lilly
LLY
+$32.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.2M
5
CHRS icon
Coherus Oncology
CHRS
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 98.21%
2 Miscellaneous 1.6%
3 Financials 0.19%
4 Consumer Staples 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEAR
101
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$1.84M 0.05%
900,548
– –
DRIO icon
102
DarioHealth
DRIO
$66.1M
$1.52M 0.04%
16,393
– –
TARA icon
103
Protara Therapeutics
TARA
$222M
$859K 0.02%
290,051
– –
HYPR icon
104
Hyperfine
HYPR
$85M
$751K 0.02%
927,388
-207,000
-18% -$292K
SONX
105
DELISTED
Sonendo, Inc.
SONX
$655K 0.02%
612,204
-36,301
-6% -$52.8K
PRVB
106
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$498K 0.01%
110,728
– –
ICVX
107
DELISTED
Icosavax, Inc. Common Stock
ICVX
$296K 0.01%
93,591
-949,259
-91% -$5.94M
MOTS
108
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$221K 0.01%
6,002
– –
EQRXW
109
DELISTED
EQRx, Inc. Warrant
EQRXW
$205K 0.01%
250,000
– –
AGRX
110
DELISTED
Agile Therapeutics
AGRX
$158K ﹤0.01%
10,647
– –
CMAXW
111
DELISTED
CareMax, Inc. Warrant
CMAXW
$113K ﹤0.01%
60,000
– –
NEPT
112
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$87K ﹤0.01%
1,429
– –
SRZNW
113
DELISTED
Surrozen Inc Warrant
SRZNW
$31K ﹤0.01%
166,666
– –
SRZN icon
114
Surrozen
SRZN
$209M
$12K ﹤0.01%
401
– –
ALNY icon
115
Alnylam Pharmaceuticals
ALNY
$31.9B
– –
-172,991
Closed -$25.2M
DAWN
116
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-556,047
Closed -$9.95M
LLY icon
117
Eli Lilly
LLY
$1.01T
– –
-100,000
Closed -$32.4M
MGNX icon
118
MacroGenics
MGNX
$257M
– –
-1,227,202
Closed -$3.62M
NUVB icon
119
Nuvation Bio
NUVB
$2.04B
– –
-1,769,701
Closed -$5.73M
PRVA icon
120
Privia Health
PRVA
$2.6B
– –
-273,423
Closed -$7.96M
RACE icon
121
Ferrari
RACE
$71.5B
– –
-6,200
Closed -$1.14M
FLNA
122
PUT
Filana Therapeutics
FLNA
$33.6M
– –
-100,000
Closed -$2.81M
XBI icon
123
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-100,000
Closed -$7.43M
FUSN
124
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-1,052,445
Closed -$2.62M
ZY
125
DELISTED
Zymergen Inc. Common Stock
ZY
– –
-883,332
Closed -$1.09M
1 2 3 4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Perceptive Advisors held 127 positions worth $3.45B, up 7.9% from $3.19B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $255M in Q3 2022, closing 11 positions and reducing 24 holdings. Its most notable exit was Eli Lilly, an estimated $32.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Edwards Lifesciences worth $27.3M.

  • Perceptive Advisors's largest Q3 2022 buy was Edwards Lifesciences: 330,000 shares worth $27.3M.
  • Perceptive Advisors added most to Relmada Therapeutics in Q3 2022, an estimated $62.7M increase.
  • Perceptive Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $38.2M.
  • Perceptive Advisors fully exited Eli Lilly in Q3 2022, selling an estimated $32.4M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q3 2022.
  • Perceptive Advisors opened 16 new positions and closed 11 in Q3 2022.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.